{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:42:46Z","timestamp":1793072566010,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologic therapies such as dupilumab and tralokinumab have greatly impacted the management of moderate-to-severe atopic dermatitis (AD). However, recent clinical observations have reported paradoxical adverse events, including psoriasis and seronegative spondyloarthropathy (SpA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the incidence, clinical characteristics and management of psoriasis and SpA in patients with AD treated with dupilumab or tralokinumab in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicentre retrospective observational study involving patients with AD receiving dupilumab or tralokinumab for \u2265 16 weeks between January 2019 and May 2025. Data were collected on patients developing psoriasis and\/or SpA, including demographics, time to onset, severity, management strategies and treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Psoriasis developed in 78 of 5899 patients (1.3%) receiving dupilumab and 16 of 769 (2.1%) on tralokinumab, with respective mean times to onset of 57.7 (SD 66.5) and 28.3 (28.9) weeks. SpA occurred in 17 patients (0.3%) on dupilumab and 1 (0.1%) on tralokinumab. Topical calcipotriol\/betamethasone was the most frequent treatment for psoriasis, while systemic agents, including methotrexate and corticosteroids, were required in refractory cases. In addition, a proportion of patients required switching to alternative biologics due to poor disease control. For SpA, management often involved systemic corticosteroids, nonsteroidal anti-inflammatory drugs or methotrexate, and upadacitinib was introduced in 41% of cases of dupilumab requiring therapeutic escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although rare, psoriasis and SpA are adverse events emerging during dupilumab or tralokinumab therapy in patients with AD. Close monitoring and prompt differential diagnosis are essential to optimize patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf483","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:13:29Z","timestamp":1761830009000},"page":"612-619","source":"Crossref","is-referenced-by-count":6,"title":["Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5607-8877","authenticated-orcid":false,"given":"Giuseppe","family":"Lauletta","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u2018Vincenzo Tiberio\u2019, University of Molise , Campobasso ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-7310","authenticated-orcid":false,"given":"Francesca","family":"Barei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Trave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Bruno","family":"Guanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Gurioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ippoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Grigolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Romita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Tirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eustachio","family":"Nettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Maria","family":"Magnanimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pezzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-8141","authenticated-orcid":false,"given":"Luca","family":"Stingeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Satta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Pigliacelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Manzo Margiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"Cascio Ingurgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natale","family":"Schettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Antiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Rubegni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lazzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8231-2205","authenticated-orcid":false,"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Valentina","family":"Puca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriele","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-5730","authenticated-orcid":false,"given":"Claudio","family":"Marasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Micali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Martina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"De Lucia","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2026032611515676200_llaf483-B1","doi-asserted-by":"crossref","first-page":"1541776","DOI":"10.3389\/fimmu.2025.1541776","article-title":"Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"issue":"4 Suppl.","key":"2026032611515676200_llaf483-B2","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2026032611515676200_llaf483-B3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/1744666X.2021.1940962","article-title":"The IL-4, IL-13 and IL-31 pathways in atopic dermatitis","volume":"17","author":"Dubin","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2026032611515676200_llaf483-B4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/cea.14263","article-title":"The evolving landscape of biologic therapies for atopic dermatitis: present and future perspective","volume":"53","author":"David E, Ungar B, Renert-Yuval Y","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"2026032611515676200_llaf483-B5","doi-asserted-by":"crossref","first-page":"1165098","DOI":"10.3389\/fmed.2023.1165098","article-title":"The hidden sentinel of the skin: an overview on the role of interleukin-13 in atopic dermatitis","volume":"10","author":"Napolitano","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026032611515676200_llaf483-B6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/ijms26020749","article-title":"Understanding the intricate pathophysiology of psoriasis and related skin disorders","volume":"26","author":"Orzan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026032611515676200_llaf483-B7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2021.05.013","article-title":"Development of psoriasis during treatment with dupilumab: a systematic review","volume":"86","author":"Brumfiel","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026032611515676200_llaf483-B8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jdcr.2024.06.044","article-title":"Paradoxical psoriasis after dupilumab treatment of prurigo nodularis treated with adalimumab","volume":"52","author":"S\u00f8rensen","year":"2024","journal-title":"JAAD Case Rep"},{"key":"2026032611515676200_llaf483-B9","first-page":"e60051","article-title":"Paradoxical eczematous reaction in a patient with IL-17 inhibitor-treated psoriasis vulgaris","volume":"16","author":"Brazen","year":"2024","journal-title":"Cureus"},{"key":"2026032611515676200_llaf483-B10","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jdv.16246","article-title":"Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review","volume":"34","author":"Al-Janabi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026032611515676200_llaf483-B11","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.3390\/jcm11195633","article-title":"The IL-4\/-13 axis and its blocking in the treatment of atopic dermatitis","volume":"11","author":"Pappa","year":"2022","journal-title":"J Clin Med"},{"key":"2026032611515676200_llaf483-B12","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17-type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2026032611515676200_llaf483-B13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ced\/llad390","article-title":"Dupilumab-associated inflammatory arthritis: a literature review","volume":"49","author":"Napolitano","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026032611515676200_llaf483-B14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12016-021-08880-3","article-title":"Update on the pathogenesis and therapy of atopic dermatitis","volume":"61","author":"Li","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026032611515676200_llaf483-B15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ced\/llaf062","article-title":"Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre study","volume":"50","author":"Barei","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026032611515676200_llaf483-B16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"key":"2026032611515676200_llaf483-B17","doi-asserted-by":"crossref","first-page":"2258240","DOI":"10.1080\/09546634.2023.2258240","article-title":"Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis","volume":"34","author":"Balakirski","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2026032611515676200_llaf483-B18","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/1346-8138.16764","article-title":"Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study","volume":"50","author":"Napolitano","year":"2023","journal-title":"J Dermatol"},{"key":"2026032611515676200_llaf483-B19","author":"SIDeMaST"},{"key":"2026032611515676200_llaf483-B20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/03009740600904243","article-title":"Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study","volume":"36","author":"De Angelis","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"2026032611515676200_llaf483-B21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"2026032611515676200_llaf483-B22","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026032611515676200_llaf483-B23","doi-asserted-by":"crossref","first-page":"e13142","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026032611515676200_llaf483-B24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13555-021-00505-z","article-title":"Efficacy and safety of dupilumab in clinical practice: one year of experience on 165 adult patients from a tertiary referral centre","volume":"11","author":"Napolitano","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026032611515676200_llaf483-B25","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1111\/jdv.17050","article-title":"De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort","volume":"35","author":"Jaulent","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026032611515676200_llaf483-B26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ijd.17397","article-title":"Tralokinumab-induced psoriasis relapse in a patient with atopic dermatitis","volume":"64","author":"Chiei Gallo","year":"2025","journal-title":"Int J Dermatol"},{"key":"2026032611515676200_llaf483-B27","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026032611515676200_llaf483-B28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdcr.2021.12.011","article-title":"Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management","volume":"21","author":"Jay","year":"2022","journal-title":"JAAD Case Rep"},{"key":"2026032611515676200_llaf483-B29","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1093\/rheumatology\/keab771","article-title":"Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib","volume":"61","author":"De Stefano","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026032611515676200_llaf483-B30","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/rheumatology\/keaa568","article-title":"Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy","volume":"60","author":"Bridgewood","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026032611515676200_llaf483-B31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ced.14050","article-title":"Acute arthritis and arthralgia as an adverse drug reaction to dupilumab","volume":"45","author":"de Wijs","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2026032611515676200_llaf483-B32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.46497\/ArchRheumatol.2022.8780","article-title":"Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis","volume":"37","author":"Bostan","year":"2021","journal-title":"Arch Rheumatol"},{"key":"2026032611515676200_llaf483-B33","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1111\/jdv.16239","article-title":"Polyenthesitis during treatment with dupilumab for atopic dermatitis","volume":"34","author":"Ishibashi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026032611515676200_llaf483-B34","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1111\/1346-8138.15872","article-title":"Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib","volume":"48","author":"Komaki","year":"2021","journal-title":"J Dermatol"},{"key":"2026032611515676200_llaf483-B35","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/annrheumdis-2021-eular.1363","article-title":"Dupilumab-induced enthesitis\/arthritis in patients with atopic dermatitis: a retrospective observational study","volume":"80","author":"Nathan","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026032611515676200_llaf483-B36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjd.19631","article-title":"Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated","volume":"184","author":"Sears","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026032611515676200_llaf483-B37","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.20138","article-title":"Dupilumab-associated arthralgia: an observational retrospective study in VigiBase\u00ae","volume":"185","author":"Chr\u00e9tien","year":"2021","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf483\/65043792\/llaf483.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/4\/612\/65043792\/llaf483.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/4\/612\/65043792\/llaf483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:52:05Z","timestamp":1774540325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/4\/612\/8307032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf483","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,10,31]]}}}